NICE is unable to make a recommendation about the use in the NHS of simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C because no evidence submission was received from Janssen for the technology.

  • National Institute for Health and Care Excellence (NICE)